[1]曾晓娇,田玲,孙毅娜.Allan-Herndon-Dudley综合征诊疗现状[J].国际内分泌代谢杂志,2023,43(04):336-340.[doi:10.3760/cma.j.cn121383-20220926-09047]
　Zeng Xiaojiao,Tian Ling,Sun Yina.Diagnosis and treatment of Allan-Herndon-Dudley syndrome[J].International Journal of Endocrinology and Metabolism,2023,43(04):336-340.[doi:10.3760/cma.j.cn121383-20220926-09047]
点击复制

Allan-Herndon-Dudley综合征诊疗现状()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年04期
页码:
336-340
栏目:
综述
出版日期:
2023-07-20

文章信息/Info

Title:
Diagnosis and treatment of Allan-Herndon-Dudley syndrome
作者:
曾晓娇; 田玲; 孙毅娜
天津医科大学朱宪彝纪念医院,天津市内分泌研究所,国家卫生健康委员会激素与发育重点实验室,天津市代谢性疾病重点实验室,天津 300134
Author(s):
Zeng Xiaojiao;  Tian Ling;  Sun Yina
NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China
关键词:
Allan-Herndon-Dudley综合征;  单羧酸转运蛋白8;  三碘甲状腺乙酸;  甲状腺激素
Keywords:
Allan-Herndon-Dudley syndrome;  Monocarboxylate transporter protein 8;  Triac;  Thyroid hormone
DOI:
10.3760/cma.j.cn121383-20220926-09047
摘要:
Allan-Herndon-Dudley综合征(AHDS)是因甲状腺激素(TH)转运体基因SLC16A2突变,致其编码单羧酸转运蛋白8(MCT8)功能失活,不能介导TH进入靶细胞引起的内分泌罕见病。主要临床表现为脑甲状腺功能减退(甲减)所致的严重神经运动发育异常,TH分泌代谢异常所致血清学(高T3、低T4、正常或轻度升高的促甲状腺激素)改变及外周组织甲状腺毒症。基因检测证实SLC16A2基因变异可确诊。有效的治疗应以改善脑甲减和外周甲状腺毒症以及恢复蛋白功能为目标。相比于激素替代治疗,T3类似物三碘甲状腺乙酸可以不依赖MCT8进入细胞,激活TH受体而发挥TH样作用,在改善患者外周甲状腺功能亢进症状上疗效显著,对神经表型可能也有效,是目前治疗AHDS较好的方法; 旨在恢复MCT8功能的基因替代和伴侣分子治疗仍处于研究阶段。
Abstract:
Allan-Herndon-Dudley syndrome(AHDS)is a rare endocrine disorder caused by mutations in the thyroid hormone(TH)transporter gene SLC16A2, resulting in the inactivation of its encoded monocarboxylate transporter protein 8(MCT8), which fails to mediate the entry of TH into target cells. The main clinical manifestations are severe neuromotor developmental abnormalities due to cerebral hypothyroidism(hypothyroidism), serological changes(high T3, low T4, normal or mildly elevated thyroid stimulating hormone)due to abnormal secretory and metabolism of TH, as well as signs of thyrotoxicity in peripheral tissues. Confirmation of the SLC16A2 gene variant by genetic testing confirms the diagnosis. Effective treatment should aim to improve cerebral hypothyroidism and peripheral thyrotoxic and restore protein function. Compared with hormone replacement therapy, T3 analog Triac, which enters cells independent of MCT8 and activates TH receptors to exert thyromimetic actions, has been shown to be effective in improving patients' peripheral hyperthyroidism symptoms and may also be effective for the neural phenotype. Currently, it is a better treatment for AHDS. In addition, gene replacement and chaperone molecules aimed at restoring the transport function of MCT8 are still in the research phase.

参考文献/References:

[1] Friesema EC,Grueters A,Biebermann H,et al.Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation[J].Lancet,2004,364(9443):1435-1437.DOI:10.1016/S0140-6736(04)17226-7.
[2] Groeneweg S,van Geest FS,Abac A,et al.Disease characteristics of MCT8 deficiency:an international,retrospective,multicentre cohort study[J].Lancet Diabetes Endocrinol,2020,8(7):594-605.DOI:10.1016/S2213-8587(20)30153-4.
[3] Groeneweg S,van Geest FS,Peeters RP,et al.Thyroid hormone transporters[J].Endocr Rev,2020,41(2):bnz008.DOI:10.1210/endrev/bnz008.
[4] 辛庆刚,赵澎,蔡春泉,等.一个导致Allan-Herndon-Dudley综合征的SLC16A2基因新突变[J].天津医药,2020,48(2):132-136.DOI:10.11958/20193176.
[5] 邹品芳,黄彦臻,黄中燕,等.SLC16A2基因变异一例报道并文献复习[J].中华脑科疾病与康复杂志(电子版),2020,10(3):183-186.DOI:10.3877/cma.j.issn.2095-123X.2020.03.012.
[6] 陆芬,张丽,汤健,等.Allan-Herndon-Dudley综合征4例并文献复习[J].中国实用儿科杂志,2022,37(7):532-536.DOI:10.19538/j.ek2022070613.
[7] 殷文晗,马彩云,吕楠.SLC16A2基因新发变异致Allan-Herndon-Dudley综合征1例[J].中国临床案例成果数据库,2022,4(1):E02722-E02722.DOI:10.3760/cma.j.cmcr.2022.e02722.
[8] Zhang Q,Yang Q,Zhou X,et al.Characteristics of Allan-Herndon-Dudley syndrome in Chinese children:identification of two novel pathogenic variants of the SLC16A2 gene[J].Front Pediatr,2022,10:1050023.DOI:10.3389/fped.2022.1050023.
[9] Zung A,Visser TJ,Uitterlinden AG,et al.A child with a deletion in the monocarboxylate transporter 8 gene:7-year follow-up and effects of thyroid hormone treatment[J].Eur J Endocrinol,2011,165(5):823-830.DOI:10.1530/EJE-11-0358.
[10] Wémeau JL,Pigeyre M,Proust-Lemoine E,et al.Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8[J].J Clin Endocrinol Metab,2008,93(6):2084-2088.DOI:10.1210/jc.2007-2719.
[11] Refetoff S,Pappa T,Williams MK,et al.Prenatal treatment of thyroid hormone cell membrane transport defect caused by MCT8 gene mutation[J].Thyroid,2021,31(5):713-720.DOI:10.1089/thy.2020.0306.
[12] Di Cosmo C,Liao XH,Dumitrescu AM,et al.A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport[J].Endocrinology,2009,150(9):4450-4458.DOI:10.1210/en.2009-0209.
[13] Ferrara AM,Liao XH,Gil-Ibáñez P,et al.Placenta passage of the thyroid hormone analog DITPA to male wild-type and Mct8-deficient mice[J].Endocrinology,2014,155(10):4088-4093.DOI:10.1210/en.2014-1085.
[14] Zada D,Tovin A,Lerer-Goldshtein T,et al.Pharmacological treatment and BBB-targeted genetic therapy for MCT8-dependent hypomyelination in zebrafish[J].Dis Model Mech,2016,9(11):1339-1348.DOI:10.1242/dmm.027227.
[15] Verge CF,Konrad D,Cohen M,et al.Diiodothyropropionic acid(DITPA)in the treatment of MCT8 deficiency[J].J Clin Endocrinol Metab,2012,97(12):4515-4523.DOI:10.1210/jc.2012-2556.
[16] Kersseboom S,Horn S,Visser WE,et al.In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency[J].Mol Endocrinol,2014,28(12):1961-1970.DOI:10.1210/me.2014-1135.
[17] Delbaere J,Vancamp P,Van Herck SL,et al.MCT8 deficiency in Purkinje cells disrupts embryonic chicken cerebellar development[J].J Endocrinol,2017,232(2):259-272.DOI:10.1530/JOE-16-0323.
[18] Groeneweg S,Peeters RP,Moran C,et al.Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency:an international,single-arm,open-label,phase 2 trial[J].Lancet Diabetes Endocrinol,2019,7(9):695-706.DOI:10.1016/S2213-8587(19)30155-X.
[19] van Geest FS,Groeneweg S,van den Akker ELT,et al.Long-term efficacy of T3 analogue Triac in children and adults with MCT8 deficiency:a real-life retrospective cohort study[J].J Clin Endocrinol Metab,2022,107(3):e1136-e1147.DOI:10.1210/clinem/dgab750.
[20] Groeneweg S,Peeters RP,Visser TJ,et al.Triiodothyroacetic acid in health and disease[J].J Endocrinol,2017,234(2):R99-R121.DOI:10.1530/JOE-17-0113.
[21] Groeneweg S,Peeters RP,Visser TJ,et al.Therapeutic applications of thyroid hormone analogues in resistance to thyroid hormone(RTH)syndromes[J].Mol Cell Endocrinol,2017,458:82-90.DOI:10.1016/j.mce.2017.02.029.
[22] Iwayama H,Liao XH,Braun L,et al.Adeno associated virus 9-based gene therapy delivers a functional monocarboxylate transporter 8,improving thyroid hormone availability to the brain of Mct8-deficient mice[J].Thyroid,2016,26(9):1311-1319.DOI:10.1089/thy.2016.0060.
[23] Liao XH,Avalos P,Shelest O,et al.AAV9-MCT8 delivery at juvenile stage ameliorates neurological and behavioral deficits in a mouse Model of MCT8-deficiency[J].Thyroid,2022,32(7):849-859.DOI:10.1089/thy.2022.0034.
[24] Braun D,Schweizer U.The chemical chaperone phenylbutyrate rescues MCT8 mutations associated with milder phenotypes in patients with Allan-Herndon-Dudley syndrome[J].Endocrinology,2017,158(3):678-691.DOI:10.1210/en.2016-1530.
[25] Ramos HE,Morandini M,Carré A,et al.Pregnancy in women heterozygous for MCT8 mutations:risk of maternal hypothyroxinemia and fetal care[J].Eur J Endocrinol,2011,164(2):309-314.DOI:10.1530/EJE-10-0679.

备注/Memo

备注/Memo:
基金项目:天津市中心妇产科医院/天津市人类发育与生殖调控重点实验室开放基金(2019XHY04); 天津市科技计划项目(18ZXZNSY00280)
通信作者:孙毅娜,Email:wssyn2003@126.com
更新日期/Last Update: 2023-08-15